(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 28.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Alnylam Pharmaceuticals's revenue in 2026 is $4,286,923,000.On average, 32 Wall Street analysts forecast ALNY's revenue for 2026 to be $760,621,128,381, with the lowest ALNY revenue forecast at $681,314,660,019, and the highest ALNY revenue forecast at $862,758,246,726. On average, 30 Wall Street analysts forecast ALNY's revenue for 2027 to be $1,000,810,247,208, with the lowest ALNY revenue forecast at $871,570,076,544, and the highest ALNY revenue forecast at $1,265,031,629,175.
In 2028, ALNY is forecast to generate $1,203,882,870,741 in revenue, with the lowest revenue forecast at $1,045,002,908,871 and the highest revenue forecast at $1,552,884,736,563.